Kelly Chibale: Learning to Fail Your Way to Success

Authors

  • Lukas Meier Swiss Tropical and Public Health-Institute, CH-4123 Allschwil, Switzerland; University of Basel, CH-4001 Basel, Switzerland

DOI:

https://doi.org/10.2533/chimia.2023.607

Keywords:

Africa, Antimalarial drugs

Abstract

A portrait is given of Professor Kelly Chibale, the driving force behind H3D, the drug discovery and development centre at the University of Cape Town, South Africa. He is dedicated to the development of new drugs to fight infectious diseases of poverty that are prevalent in Africa, including MMV390048, the first anti-malarial drug ever to be validated in a Phase I trial in Africa. In 2018 he was recognized as one of Fortune magazine’s top 50 ‘World’s Greatest Leaders’.

Downloads

Published

2023-09-20

Issue

Vol. 77 No. 9 (2023): Swiss TPH: 30 Years of R&D Towards New Drugs for Tropical Diseases

Section

Scientific Articles

License

Copyright (c) 2023 Lukas Meier

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Chimia 2023, 77, 607, DOI: 10.2533/chimia.2023.607.